# Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD

> **NCT01213992** · PHASE1 · COMPLETED · sponsor: **Pharmacosmos A/S** · enrollment: 16 (actual)

## Conditions studied

- Non-dialysis Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Iron isomaltoside 1000
- **DRUG:** Iron isomaltoside 1000

## Key facts

- **NCT ID:** NCT01213992
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213992, "Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01213992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*